Browsing Tag
biotech
31 posts
Nasdaq: KOD — Is Kodiak Sciences’ KSI-101 finally turning Wall Street bullish on ocular inflammation?
Explore how Kodiak Sciences’ KSI‑101 is reshaping the retinal‑disease treatment landscape and why JPMorgan just upgraded the stock—read more now!
Ventyx Biosciences announces positive Phase 2 trial data for VTX3232 in obesity and cardiometabolic risk
Find out how Ventyx Biosciences’ VTX3232 is reshaping the obesity and cardiometabolic space through inflammation-targeted innovation.
Can Invion Limited (ASX: IVX) unlock new growth by taking Photosoft into pet cancer care?
Invion signs a new funded deal with Protect Animal Health to test Photosoft in pet cancer care. Can this pivot unlock faster returns for the ASX-listed biotech?
How Celcuity Inc.’s gedatolisib trial results sent its stock soaring 46% in a single morning
Celcuity stock surged 46% after Phase 3 trial data showed strong efficacy for gedatolisib in HR+/HER2- breast cancer. Find out what this means for investors.
NextCure brings Simcere Zaiming’s SIM0505 to U.S. trials as ADC race accelerates in oncology
Find out how NextCure and Simcere Zaiming are expanding SIM0505’s Phase 1 program into the U.S. and redefining the future of ADC collaboration.
Humacyte’s $60mn funding boost sparks mixed investor reaction over equity dilution
Humacyte raises $60 million in an oversubscribed direct offering as investors debate dilution risks and long-term biotech value. Read the analysis.
Oxford Biomedica (LSE: OXB) expands US manufacturing base with Durham viral vector facility buy
Find out how Oxford Biomedica’s new US viral vector facility strengthens its CDMO leadership and growth trajectory.
Why Q/C Technologies’ 6.51m share registration could reshape its stock outlook in 2025
Discover why Q/C Technologies plans to register 6.51M shares for resale, what it signals to investors, and how it could impact QCLS stock.
DXB rockets on Japan orphan drug win — can Dimerix finally deliver an FSGS breakthrough?
Dimerix (ASX: DXB) secures orphan drug designation in Japan for DMX-200, strengthening its global Phase 3 kidney trial program. Find out what’s next.
Paradigm Biopharmaceuticals (ASX: PAR) hits key Phase 3 milestone as dosing begins in U.S. and Australia
Paradigm Biopharmaceuticals (ASX: PAR) begins dosing in its pivotal Phase 3 osteoarthritis trial, setting up a mid-2026 data readout that could redefine its future.